4-羟基-1-苯基吡唑并[3,4-D]嘧啶 | 21314-17-0

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-羟基-1-苯基吡唑并[3,4-D]嘧啶
• 中文别名: 4-羟基-1-苯基吡唑[3,4-d]嘧啶
• 英文名称: 1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one；1-phenyl-pyrazolo-[3,4-d]-pyrimidin-4-one；1,5-dihydro-1-phenyl-4H-pyrazolo(3,4-d)pyrimidin-4-one；1-phenyl-5H-pyrazolo[3,4-d]pyrimidin-4-one
• CAS: 21314-17-0
• 化学式: C₁₁H₈N₄O
• mdl: MFCD00082637
• 分子量: 212.211
• InChiKey: GDZQGHGCKKWNAC-UHFFFAOYSA-N

物化性质

• 熔点：
  304-307 °C
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338,P302+P352,P321,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密封装的容器中。储存在阴凉、干燥的地方。

SDS

Name:	4-Hydroxy-1-phenylpyrazole[3 4-d]pyrimidine 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	21314-17-0

Section 1 - Chemical Product MSDS Name:4-Hydroxy-1-phenylpyrazole[3 4-d]pyrimidine 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
21314-17-0	4-Hydroxy-1-phenylpyrazole[3,4-d]pyrim	98%	244-331-0

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 21314-17-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 304 - 307 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H8N4O
Molecular Weight: 212.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 21314-17-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Hydroxy-1-phenylpyrazole[3,4-d]pyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 21314-17-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 21314-17-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 21314-17-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-羟基-1-苯基吡唑并[3,4-D]嘧啶 在 三乙胺 、 三氯氧磷 作用下， 反应 4.0h， 生成 4-氯-1-苯基-1H-吡唑并[3,4-d]嘧啶
  参考文献：
  名称：

  Synthesis and in vitro antiproliferative activity of novel pyrazolo[3,4-d]pyrimidine derivatives

  摘要：

  一系列新型吡唑并[3,4-d]嘧啶衍生物被设计、合成并评估其抗增殖活性。

  DOI：

  10.1039/c5md00127g
• 作为产物：
  描述：

  5-氨基-4-氰基-1-苯基-1H-吡唑-3-甲酸乙酯 以 水 为溶剂， 反应 7.17h， 生成 4-羟基-1-苯基吡唑并[3,4-D]嘧啶
  参考文献：
  名称：

  Abdelhamid, Abdou O., Journal of Chemical Research, Miniprint, 1993, # 6, p. 1239 - 1262

  摘要：

  DOI：

文献信息

• Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties
  作者：Kanagasabai Somakala、Sana Tariq、Mohd. Amir

  DOI：10.1016/j.bioorg.2019.03.037

  日期：2019.6

  property, antioxidant assay and p38α MAP kinase inhibition. The in vitro anti-inflammatory assay results revealed that the compounds (6f-i) showed better activity than the compounds 6a-e. Compound 6f bearing the 4-chlorophenyl group showed in vitro anti-inflammatory activity (82.35 ± 4.04) comparable to standard drug diclofenac sodium (84.13 ± 1.63) and better p38α MAP kinase inhibitory activity (IC50 = 0

  合成了一系列九种新的N-取代的-4-（（1-苯基-1H-吡唑并[3,4-d]嘧啶-4-基）氨基）苯甲酰胺（6a-i）衍生物。体外筛选了所有化合物的BSA抗变性，抗氧化剂测定和p38αMAP激酶抑制作用。体外抗炎测定结果表明，化合物（6f-i）显示出比化合物6a-e更好的活性。带有4-氯苯基的化合物6f在体外具有抗炎活性（82.35±4.04），与标准药物双氯芬酸钠（84.13±1.63）相当，并且比原型抑制剂具有更好的p38αMAP激酶抑制活性（IC50 = 0.032±1.63 µM）。 SB203580（IC50 = 0.041±1.75 µM）。在动物模型中进一步研究了所选的活性化合物（6f-i）的抗炎活性，致溃疡性，脂质过氧化和TNF-α抑制潜力。与标准双氯芬酸钠（78.05％）相比，化合物6f显示出令人鼓舞的抗炎潜力，抑制百分比为83.73％。与标准品相比，还发现化合物6f具有降低的致溃疡作用和脂质过氧化作用。与SB
• PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160185785A1

  公开（公告）日：2016-06-30

  The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X 1 , X 2 , R 1 -R 5 , R 5′ and R 6 are described herein.

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。
• Synthesis of aminocyanopyrazoles via a multi-component reaction and anti-carbonic anhydrase inhibitory activity of their sulfamide derivatives against cytosolic and transmembrane isoforms
  作者：Fatma Allouche、Fakher Chabchoub、Fabrizio Carta、Claudiu T. Supuran

  DOI：10.3109/14756366.2012.720573

  日期：2013.4.1

  were converted to the corresponding sulfamides by reaction with sulfamoyl chloride. The aminopyrazoles incorporating phenyl and tosyl moieties were tested as inhibitors of four carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human (h) hCA I, II, IX and XII. Many of them showed low micromolar or submicromolar inhibition of these enzymes. The corresponding sulfamides were low nanomolar CA inhibitors.

  描述了在酸性催化剂下丙二腈与原酸酯和肼衍生物之间多组分反应（MCR）的便捷方案。制备，分离和表征了一系列氨基氰基吡唑4。这些吡唑与亚硝酸钠，然后与仲胺试剂和甲酸反应，生成吡唑并三嗪6和吡唑并吡喃二酮7。一些氨基吡唑通过与氨磺酰氯反应转化为相应的磺酰胺。测试了结合有苯基和甲苯磺酰基部分的氨基吡唑类化合物作为四种碳酸酐酶（CA，EC 4.2.1.1）同种型（人）hCA I，II，IX和XII的抑制剂。它们中的许多显示出对这些酶的低微摩尔或亚微摩尔抑制。相应的磺酰胺为低纳摩尔CA抑制剂。
• [EN] ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS D'ECTONUCLÉOTIDES PYROPHOSPHATASES/PHOSPHODIESTÉRASES 1 (ENPP1) ET LEURS UTILISATIONS
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2021133915A1

  公开（公告）日：2021-07-01

  Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

  本文提供了外胞核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）的小分子调节剂，包括这些化合物的组合物，以及使用这些化合物和包含这些化合物的组合物的方法。
• Preparation of Nitrogen-Containing π-Deficient Heteroaromatic Grignard Reagents:  Oxidative Magnesiation of Nitrogen-Containing π-Deficient Halogenoheteroaromatics Using Active Magnesium
  作者：Osamu Sugimoto、Shigeru Yamada、Ken-ichi Tanji

  DOI：10.1021/jo026492a

  日期：2003.3.1

  The oxidative magnesiation of nitrogen-containing pi-deficient halogenoheteroaromatics using active magnesium was accomplished. Both magnesiation followed by addition of a carbonyl compound (Grignard reaction) and magnesiation in the presence of a carbonyl compound (Barbier reaction) were carried out to afford the corresponding product. Especially, the latter method enabled fused halogenodiazines such

  使用活性镁完成了含氮pi不足的卤代杂环芳烃的氧化放大作用。进行镁的放大，然后添加羰基化合物（格氏反应），以及在羰基的化合物存在下进行镁的放大（Barbier反应），得到相应的产物。特别地，后一种方法使稠合的卤素二嗪例如4-氯-1-苯基-1H-吡唑并[3，4-d]嘧啶或2-氯喹喔啉在温和的温度（-20至30℃）下氧化镁。

表征谱图